| Strategy to Manage Irritable Bowel Syndrome in Korea |
|
Jeong Hwan Kim, In-Kyung Sung |
|
Department of Internal Medicine, Konkuk University School of Medicine, Seoul, Korea |
| 과민성장증후군 치료전략: 언제, 어떤 약을 사용할 것인가? |
|
김정환, 성인경 |
|
건국대학교 의학전문대학원 소화기내과 |
Correspondence:
In-Kyung Sung, Tel: +82-2-2030-6182, Fax: +82-2-2030-8290, Email: 2005005@kuh.ac.kr
|
|
|
|
|
| This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/3.0/) which permits unrestricted noncommercial use, distribution, and reproduction in any medium, provided the original work is properly cited. |
|
| Abstract |
|
Irritable bowel syndrome (IBS) is one of the most prevalent functional gastrointestinal disorders. It is a multi-factorial disorder due to abnormal gastrointestinal motility, low-grade inflammation, visceral hypersensitivity, and communication between the gut-brain axis. IBS is traditionally treated with dietary and lifestyle modifications, fiber supplementation, and psychological and pharmacological therapies. Diet therapy including the low FODMAP diet and excluding certain food constituents is often used. Antispasmodics plus stool consistency modifiers to treat the major symptoms and defecation are first-line drug treatments. 5-Hydroxytryptamine (5-HT) receptors in the gastrointestinal tract, particularly 5-HT3 and 5-HT4 receptors are involved not only in modulating gut motility but in visceral sensory pathways. Drugs that act on both receptor classes appear to reduce visceral sensitivity and have inhibitory effects on motor activity in the distal intestine. 5-HT4 agonists may improve constipationpredominant IBS by normalizing bowel habits and thereby reduce abdominal pain. IBS continues to be a therapeutic challenge because of its diverse symptomatology and lack of a single pathophysiological target for drug intervention. (Korean J Med 2014;86:695-697) |
| Key Words:
Irritable bowel syndrome; low FODMAP diet; 5-HT4 agonists |
| 주제어:
과민성장증후군; 저 FODMAP 식이; 세로토닌 4형 수용체 작용제 |
|
PDF Links
Full text via DOI
Download Citation
